Key Points Management's medium-term sales target for its Zoryve franchise pleased investors. Its near-term sales estimate for 2026 also blasted past analyst estimates. 10 stocks we like better than Arcutis Biotherapeutics › Shares in Arcutis Biotherapeutics (NASDAQ: ARQT) soared by almost 30% in trading to 10:30 a.m. ET today. The move comes after an excellent set of third-quarter earnings and an investor day presentation replete with positive near- and medium-term guidance that exceeded analyst ex ...